Sun Pharmaceutical Industries Ltd.
Stock Scores
94.9 / 100
32.6 / 100
80.1 / 100
87.6 / 100
Key Metrics
Stock Analysis
Fundamental analysis overview of Sun Pharmaceutical Industries Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Strong price momentum
Price Momentum score of 80.1 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term
What is Price Momentum score?
80.1 / 100
High and stable operating margin
The company reported strong operating margin of 22.93% for 12-month ended 30 Jun 2026 and operating margin declined marginally by -101 bps from 1 year ago
What is Operating profit margin?
Moderate EPS growth and above median growth of industry
The company delivered moderate EPS growth of 14.91% for 12-month ended 30 Jun 2026 and the growth was 7.71 percentage points higher than median growth of industry
What is EPS growth (1Y)?
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.06 as on 30 Jun 2026 and Debt to Equity increased marginally by 0.03 in the last 1 year
What is Debt to Equity?
Consistently pays dividend
The company has not missed dividend payments once in the last 10 financial years
What is Dividend streak?
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Expensive and at a premium to industry median P/E
PE TTM of 37.74 indicates that the stock is expensive on a standalone basis and is at a 22.93% premium to industry median P/E
What is P/E Ratio?
Analysts have been downgrading forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has decreased by -0.73% in the last 3 months, indicating weak earnings momentum
What is Earnings upgrade (3M)?
Low dividend yield
The company has a low dividend yield of 0.84%
What is Dividend yield?
Moderate and stable ROE
The company reported moderate ROE of 14.74% for 12-month ended 30 Jun 2026 and ROE declined marginally by -135 bps from 1 year ago
What is ROE (FY)?
Moderate revenue growth and in line with median growth of industry
The company delivered moderate revenue growth of 11.41% for 12-month ended 30 Jun 2026 and the growth was 0.82 percentage points higher than median growth of industry
What is Sales growth (1Y)?
Company's earnings are of moderate quality
Earnings quality score of 57.5 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
57.5 / 100
Financial Snapshot
See detailed analysisMulti-year trends for Sun Pharmaceutical Industries Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Holdings and Presence
Indices and prominent investors with a stake in this stock.
| # | Index | Weight | Rank |
|---|---|---|---|
| 1 | Nifty Pharma | 21.34% | 1 / 20 |
| 2 | Nifty Healthcare | 18.34% | 1 / 20 |
| 3 | Nifty 100 Low Volatility 30 | 3.75% | 3 / 30 |
| 4 | Nifty Alpha Low Vol 30 | 3.62% | 10 / 30 |
| 5 | Nifty 50 Equal Weight | 2.08% | 14 / 50 |
| 6 | Nifty 50 | 1.89% | 15 / 50 |
| 7 | Nifty 100 | 1.54% | 15 / 100 |
| 8 | Nifty 500 | 1.06% | 15 / 499 |
| 9 | Nifty 100 Equal Weight | 1.04% | 26 / 100 |
| 10 | Nifty Total Market | 1.01% | 15 / 749 |
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Sun Pharmaceutical Industries Ltd. shares as reported to NSE and BSE.
| Name | Month | Transaction | Holding % pre transaction | Average price | Qty. | Transaction value |
|---|---|---|---|---|---|---|
Sailesh T. Desai Director | March-2023 | Market Sale (Disposal) 20th Mar 2023 | 0.10 % | ₹ 965.74 | 4.00 k | ₹ 38.63 lac |
Sailesh T. Desai Director | December-2022 | Market Sale (Disposal) 23rd Dec 2022 | 0.10 % | ₹ 1,028.14 | 5.00 k | ₹ 51.41 lac |
Sailesh T. Desai Director | December-2022 | Market Sale (Disposal) 23rd Dec 2022 | 0.10 % | ₹ 1,021.60 | 2.00 k | ₹ 20.43 lac |
Sailesh T. Desai Director | December-2022 | Market Sale (Disposal) 23rd Dec 2022 | 0.10 % | ₹ 1,025.00 | 2.00 k | ₹ 20.50 lac |
Nilesh Gandhi Designated Person | December-2022 | Market Sale (Disposal) 8th Dec 2022 | 0.00 % | ₹ 1,028.54 | 2.00 k | ₹ 20.57 lac |
Priti Gandhi Immediate Relative | December-2022 | Market Sale (Disposal) 8th Dec 2022 | 0.00 % | ₹ 1,030.00 | 3.00 k | ₹ 30.90 lac |
Desai Associates Partnership firm in which Ms. Meera Desai wife of Mr. Sailesh T. Desai Whole-time Director is one of the partners Other | December-2022 | Market Sale (Disposal) 2nd Dec 2022 | 0.01 % | ₹ 1,055.00 | 1.00 k | ₹ 10.55 lac |
Sailesh T. Desai Director | December-2022 | Market Sale (Disposal) 1st Dec 2022 | 0.09 % | ₹ 1,047.63 | 6.00 k | ₹ 62.86 lac |
Desai Associates Partnership firm in which Meera Desai wife of Sailesh T. Desai WTD is a Partner Other | December-2022 | Market Sale (Disposal) 1st Dec 2022 | 0.01 % | ₹ 1,049.00 | 1.00 k | ₹ 10.49 lac |
Sailesh T. Desai Director | November-2022 | Market Sale (Disposal) 25th Nov 2022 | 0.09 % | ₹ 1,030.45 | 10.00 k | ₹ 1.03 cr |
Corporate Actions
History of Sun Pharmaceutical Industries Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
- Dividend₹ 5/shareRecord date: 7th Jul 2026Ex-date: 7th Jul 2026Announced on: 22nd May 2026
- Dividend₹ 11/shareRecord date: 5th Feb 2026Ex-date: 5th Feb 2026Announced on: 20th Jan 2026
- Dividend₹ 5.50/shareRecord date: 7th Jul 2025Ex-date: 7th Jul 2025Announced on: 22nd May 2025
- Dividend₹ 10.50/shareRecord date: 6th Feb 2025Ex-date: 6th Feb 2025Announced on: 16th Jan 2025
- Dividend₹ 5/shareRecord date: 12th Jul 2024Ex-date: 12th Jul 2024Announced on: 22nd May 2024
Company Profile
Overview of Sun Pharmaceutical Industries Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.